Related Experiment Video

Updated: Aug 21, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Recent Discovery of PARP7 Inhibitors as Anticancer Agents

Robert B Kargbo1

  • 1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.

ACS Medicinal Chemistry Letters
|November 17, 2022
PubMed

Insights

New treatments targeting Poly (ADP-ribose) polymerase 7 (PARP7) inhibitors show promise for improving survival rates in advanced ovarian and pancreatic cancers. This patent disclosure offers novel therapeutic strategies for these challenging malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Advanced ovarian cancer survival rates remain critically low, below 30% over 5 years, with stagnant progress.
  • Existing treatments for ovarian and pancreatic cancers have limited efficacy in advanced stages.

Discussion:

  • This patent discloses novel Poly (ADP-ribose) polymerase 7 (PARP7) inhibitors.
  • These inhibitors represent a potential new therapeutic avenue for difficult-to-treat cancers.

Key Insights:

  • PARP7 inhibitors are highlighted as a key focus for therapeutic development.
  • The disclosed methods aim to address unmet needs in advanced ovarian and pancreatic cancer treatment.

Outlook:

  • Further research and clinical trials are warranted to evaluate the efficacy and safety of these PARP7 inhibitors.
  • Successful development could lead to improved patient outcomes and survival rates for ovarian and pancreatic cancer patients.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K